Results 11 to 20 of about 277,103 (274)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE

open access: yesBMJ Open, 2022
Introduction Randomised controlled trials (RCTs) may use surrogate endpoints as substitutes and predictors of patient-relevant/participant-relevant final outcomes (eg, survival, health-related quality of life).
Martin Offringa   +10 more
doaj   +8 more sources

Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease [PDF]

open access: yesEClinicalMedicine
Summary: The judicious use of surrogate endpoints as substitutes for patient relevant target outcomes can substantially reduce the size and duration of clinical trials, thereby driving down research and development costs and driving faster patient access
Rod S. Taylor   +9 more
doaj   +2 more sources

The Evaluation of Surrogate Endpoints

open access: yes, 2005
Both humanitarian and commercial considerations have spurred intensive search for methods to reduce the time and cost required to develop new therapies.
Molenberghs, Geert   +2 more
core   +3 more sources

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more [PDF]

open access: yesBMJ Oncology
Clinical endpoints, such as overall survival, directly measure relevant outcomes. Surrogate endpoints, in contrast, are intermediate, stand-in measures of various tumour-related metrics and include tumour growth, tumour shrinkage, blood results, etc ...
Vinay Prasad   +4 more
doaj   +2 more sources

Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies

open access: yesКардиоваскулярная терапия и профилактика, 2022
The importance of high-quality randomized controlled trials cannot be overemphasized. Each such study attempts to answer a specific clinical question. To do this, it is necessary to determine in advance the indicator of achievement of a specific result ...
A. R. Navasardyan, S. Yu. Martsevich
doaj   +1 more source

Surrogate endpoints for neonatal outcome: A rapid review [PDF]

open access: yesHealth Science Reports
Shiraz El Adam   +3 more
doaj   +2 more sources

Patient Centered Outcomes in Periodontal Treatment-An Evidenced Based Approach [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2017
Transformation of research into clinical practice is the most challenging step in evidence based dental practice. Designing the most reliable research with applicable endpoint evaluation is very important as it can lead to successful research outcomes ...
Ekta Bharatbhai Shah   +3 more
doaj   +1 more source

The perils of surrogate endpoints [PDF]

open access: yesEuropean Heart Journal, 2015
Our goals in medicine are (i) to improve the quality of patients' lives, (ii) help them to live longer, and (iii) to do so at a reasonable cost. These are our true endpoints: health status, survival, and cost. It is thus entirely consistent with this point of view that these are the fundamental concepts that can be united in a formal cost–utility ...
Weintraub, William S   +2 more
openaire   +4 more sources

Incorporating Covariates into Measures of Surrogate Paradox Risk

open access: yesStats, 2023
Clinical trials often collect intermediate or surrogate endpoints other than their true endpoint of interest. It is important that the treatment effect on the surrogate endpoint accurately predicts the treatment effect on the true endpoint.
Fatema Shafie Khorassani   +3 more
doaj   +1 more source

Selection of Endpoints for Clinical Studies of Ophthalmic Drugs

open access: yesРегуляторные исследования и экспертиза лекарственных средств, 2021
Until now, there have been no effective treatments for some ophthalmic diseases that have high social significance. Development of therapeutic approaches to such diseases may be complicated due to challenges in diagnosis and selection of clinical trial ...
M. O. Komarova
doaj   +1 more source

Home - About - Disclaimer - Privacy